Finance

Lists
RAPP:NASDAQ
Rapport Therapeutics Inc
$45.77
0.00%
(0.00) 1D
Sep 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RAPP...
Mkt. cap
2.20B
Avg. vol.
281.79K
Volume
724.00
52-wk high
$52.93
52-wk low
$22.06
EPS
-$3.04
Shares outstanding
47.98M
No. of employees
84
Mkt. cap
2.20B
Avg. vol.
281.79K
Volume
724.00
52-wk high
$52.93
52-wk low
$22.06
EPS
-$3.04
Shares outstanding
47.98M
No. of employees
84
About Rapport Therapeutics Inc
CEO-
Employees84
Founded2022
HeadquartersBoston, Massachusetts, United States
SectorPharmaceutical industry
Websiterapportrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to RAPP in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RAPP in the last 3 months.
Highest
Current $45.77
$75.00 (+63.86%)
Average
$60.25 (+31.64%)
Lowest
$50.00 (+9.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Justin Walsh
JonesTrading
Buy
Maintained
$50.00
+9.2%
09/02/2026
Kambiz Yazdi
BTIG
Buy
Maintained
$65.00
+42%
08/27/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/19/2026
Tiago Fauth
Raymond James
Buy
Maintained
$75.00
+63.9%
08/17/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$66.00
+44.2%
08/17/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$56.00
+22.4%
08/13/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$62.00
+35.5%
08/05/2026
Danielle Brill
Truist Financial
Buy
Maintained
$56.00
+22.4%
08/06/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
07/17/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$52.00
+13.6%
06/24/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$46.00
+0.5%
04/22/2026
Unknown Analyst
Raymond James
Buy
Initiated
$66.00
+44.2%
04/09/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
20.00M
-
Cost of goods sold
-
-
32.72M
51.41M
Cost of revenue
-
-
32.72M
51.41M
Research and development expenses
22.28M
30.26M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.71M
8.25M
11.50M
9.39M
Operating expense
29.99M
38.51M
11.50M
9.39M
Total operating expenses
29.99M
38.51M
44.22M
60.81M
Operating income
-29.99M
-38.51M
-24.22M
-60.81M
Other non operating income
-
-
-
-
EBT including unusual items
-26.92M
-33.76M
-19.86M
-56.62M
EBT excluding unusual items
-26.92M
-33.76M
-19.86M
-56.62M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.92M
-33.76M
-19.86M
-56.62M
Net profit margin
-
-
-99.28%
-
Earnings per share
-0.71
-0.72
-0.42
-1.19
Interest and investment income
3.06M
4.75M
4.36M
4.19M
Interest expense
-
-
-
-
Net interest expenses
3.06M
4.75M
4.36M
4.19M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.73M
-38.24M
-23.99M
-60.59M
Gain or loss from assets sale
-
-
153.00K
-1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps